Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025
PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. ('Starton'), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the presentation of positive data from a Phase 1b study evaluating STAR-LLD for the treatment of multiple myeloma (MM) at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place in Chicago, IL, from April 25-30, 2025.
'We are pleased to present the positive results from our Phase 1b study at this year's AACR meeting, which demonstrate the significant potential of our continuous low dose lenalidomide therapy, STAR-LLD, to treat patients with relapsed/refractory multiple myeloma,' said Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics.' Treatment with STAR-LLD also demonstrated impressive tolerability data, suggesting a highly differentiated and favorable safety profile. Based on the strength of these data, we look forward to advancing STAR-LLD into a Phase 2 clinical trial in the coming months.'
Poster Presentation Details:
Title: Continuous subcutaneous lenalidomide delivery improves the therapeutic index and avoids drug-related grade 3/4 hematologic toxicity in patients with relapsed/refractory multiple myelomaAbstract Presentation Number: LB207Session Title: Late-Breaking Research: Clinical Research 1Session Date and Time: Monday, April 28th at 2pm Location: Poster Section 53Poster Board Number: 4Presented by: Nashat Gabrail, MD, Gabrail Cancer & Research Center
Phase 1b results:
Six relapsed/refractory MM patients were enrolled from two U.S. community-based investigational sites in the Phase 1b study. Median age was 73, male to female ratio 1/1, Caucasian 100%, and median lines of previous therapy were 2 (range 1-7). Two patients were refractory and four were relapsed to their prior treatment. Four patients were previously exposed to lenalidomide, one of which was discontinued from a prior regimen because of severe fatigue, and all six had received prior bortezomib. Patients received 3-12 cycles of study therapy.
No patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy.
Non-hematologic toxicities did not exceed Grade 2
The PK/PD data minimized Cmax and lowered AUC while achieving biologically active doses and reducing toxicity
STAR-LLD pharmacokinetics produced median steady-state blood levels (Cmax) of 39 ng/mL (N=6) and were above the minimum target of 25 ng/mL.
All six patients receiving STAR-LLD achieved an objective response (1 CR and 5 PRs); one patient who achieved a partial response experienced a Grade 2 skin reaction during cycle 3 and withdrew from the study
Continuous treatment with STAR-LLD does not appear to significantly increase immune checkpoints associated with T cell exhaustion
Five patients are continuing treatment per protocol with a median PFS of > 10 months
Conclusion: Continuous delivery of low dose lenalidomide (STAR-LLD) provides meaningful efficacy and improved tolerability with no grade >3 drug-related hematologic toxicity. Further studies in MM and chronic lymphocytic leukemia are planned.
About STAR-LLDSTAR-LLD is a continuous delivery lenalidomide (LLD) in development to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD and 20% of animals in this cohort were tumor-free after 100 days, compared to a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1 bioavailability study in healthy men comparing subcutaneous STAR-LLD to Revlimid® demonstrated the drug is well tolerated and is >91% bioavailable by the subcutaneous route. It was also observed that the Cmax is <90% lower than oral Revlimid®.
About Starton Therapeutics
Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit www.startontx.com.
Forward Looking Statements
All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding our plans and objectives for future operations and expectations about current and future clinical trials, constitute 'forward-looking statements.' Forward-looking statements are subject to numerous conditions and known and unknown risks and uncertainties that could cause our actual results or events to differ materially from those included within the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and except as required by law, Starton undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Investor Relations Contact
Alex StarrManaging Director LifeSci Advisors astarr@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
XRP Price Consolidates for 200 Days, PFMCrypto Launches XRP Mining Contract to Unlock a New Profit Model for XRP
Farington, England, June 20, 2025 (GLOBE NEWSWIRE) — What Is PFMCrypto XRP Cloud Mining? PFMCrypto cloud mining is a remote digital asset mining platform that enables users to earn cryptocurrency by renting computing power from PFMCrypto's eco-friendly, high-performance mining farms. Supporting a broad array of coins—including XRP, DOGE, BTC, LTC, SOL, etc. —PFMCrypto removes the technical and financial obstacles traditionally associated with crypto mining, making passive income more accessible than ever. Check the official website for details: Key Highlights of the XRP Cloud Mining Contract: – Strategic Launch Timing: The contract was launched during a period of XRP price consolidation, offering investors a way to profit regardless of short-term market moves. – Stable Passive Returns: PFMCrypto's new XRP contract provides fixed daily payouts with guaranteed principal return, appealing to both traders and long-term holders. – No Technical Barriers: The XRP mining model requires no hardware or maintenance—any user can participate instantly. New Profit Model: XRP Mining Meets AI Optimization PFMCrypto's AI-powered mining architecture now supports XRP-specific contracts, leveraging intelligent allocation of hash power to maximize yields while reducing risk. This model is especially timely, given that XRP has traded in a narrow band for months, signaling the perfect moment for alternative yield strategies. Rather than waiting for a price breakout, PFMCrypto users can now earn XRP daily through smart mining contracts—without buying more tokens or attempting to time the market. Why This XRP Mining Contract Stands Out? – 100% Remote Access: No rigs, no tech know-how—just log in and activate a plan. – Principal Security: Contract terms guarantee full capital return after expiration. – AI-Driven Returns: Yield optimization ensures users earn even during price stagnation. – Daily Earnings: Predictable XRP payouts improve cash flow and reduce volatility exposure. Join PFMCrypto and receive a $10 sign-up bonus to begin XRP mining immediately. PFMCrypto's CEO commented, 'We view XRP's consolidation not as stagnation, but as opportunity. Our new mining contract allows the XRP community to unlock value from this asset in a consistent, low-risk way.' Proven Mining Models for XRP Investors PFMCrypto's XRP mining contracts have already shown strong user interest across multiple tiers. Sample return rates include: 2-Day Plan: +6.0% return and $2 Bonus 5-Day Plan: +6.15% return 15-Day Plan: +20.7% return 30-Day Plan: +47.1% return These results are based on historical contract data and reflect PFMCrypto's commitment to transparency and performance. How to Start Mining XRP with PFMCrypto Sign Up: New users receive a $10 welcome bonus and $0.60 daily login rewards. Select a Contract: Choose from flexible XRP mining durations to match your investment goals. Start Earning: PFMCrypto's AI-driven engine takes care of the rest—earning begins immediately upon activation. About PFMCrypto Founded in 2018, PFMCrypto is a leading provider of AI-powered cloud mining services. With over 9.2 million users in 190+ countries, the platform has paid out more than $1 billion in crypto rewards. Its offerings span BTC, LTC, XRP, DOGE, and more—enabling secure, hardware-free mining experiences backed by top-tier infrastructure. Explore the future of XRP mining at Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
2 hours ago
- Business Upturn
Cost-Saving Air Filtration for Ontario Schools: Expert Insights from Camfil Canada Air Quality Specialist Joshua Guthrie
Toronto, ON, June 20, 2025 (GLOBE NEWSWIRE) — Indoor air quality (IAQ) plays a crucial role in creating a healthy and productive learning environment for students and staff in Ontario schools. Camfil Canada has launched a new article and accompanying video focusing on how schools in Ontario can save money on air filtration costs while improving indoor air quality. The resources are designed to help school boards and administrators tackle rising operational costs in a practical, effective way. The article, How Canadian Schools Can Save Money and Create Healthier Learning Environments , highlights the growing financial pressures faced by Canadian schools and introduces innovative ways to cut expenses related to HVAC systems and air filter maintenance. The video further supports this message by detailing real-world examples of cost-saving strategies implemented in Ontario schools, including the use of advanced air filters with high dust-holding capacities and energy-efficient designs. 'As school boards across Canada face funding pressures and seek to decrease operational costs, they could be overlooking an expense that could achieve significant savings for schools,' said Joshua Guthrie, Life Science Segment Leader and NAFA Certified Air Filtration Specialist at Camfil Canada, 'The type of air filter used could be costing Canadian schools far too much in terms of energy consumption, labour for changeouts and maintenance, and filter replacement costs.' Key topics covered include how premium filters can extend service life, reduce waste, lower energy consumption, and decrease overall HVAC system strain. Notably, Camfil Canada's team emphasizes on-site testing and Life Cycle Cost analysis (LCC) as essential tools for tailoring filtration solutions to a specific school's needs. The article also sheds light on the impressive results achieved by some Ontario school boards, where transitioning to advanced filtration systems resulted in reduced filter replacement costs and significant energy savings. One Ontario school board, for instance, saved over $500,000 in filter costs alone by adopting Camfil's air filter solutions. To learn more about how school districts can save on energy costs while improving air quality in Ontario schools, read Camfil Canada's full article and watch the accompanying video. To access these resources, see the article at Camfil Canada or watch the full video on YouTube here. About Camfil Canada For more than 60 years, Camfil has been helping people breathe cleaner air. As a leading manufacturer of premium clean air solutions, we provide commercial and industrial systems for air filtration and air pollution control that improve worker and equipment productivity, minimize energy use, and benefit human health and the environment. Media Contact: Phillip Ilijevski Phone: 437-929-1161 Email: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
2 hours ago
- Business Upturn
Media Advisory: Astro Yogurt Brand Unveils 'So Canadian' Flyover Welcome Message for Toronto Pearson International Airport Arriving Passengers, Ahead of Canada Day
By GlobeNewswire Published on June 20, 2025, 22:48 IST TORONTO, June 20, 2025 (GLOBE NEWSWIRE) — On Monday, June 23, 2025, media are invited to attend a special event at Lactalis Canada's yogurt processing facility in Etobicoke, Ontario as part of its iconic Astro yogurt brand's bold new 'So Canadian' campaign in the lead up to Canada Day. WHAT: The unveiling of a special rooftop mural at Astro's processing facility adjacent to and on the flight path of Toronto Pearson International Airport. The uniquely Canadian rooftop mural will be visible to passengers flying into the Toronto airport, reflecting the kind, warm and inclusive identity that defines Canadians. The event will also include remarks from Lactalis Canada President & CEO Mark Taylor and other company executives, government and community partners, a photo opportunity with a giant Astro yogurt tub and Canadian-inspired festivities. WHEN: Monday, June 23, 2025 • Media Registration: 10:30 a.m. • Opening Ceremony: 11:00 a.m. to 11:30 a.m. • Photo Opportunity: 11:35 a.m. Media are encouraged to arrive at 10:30 a.m. for registration. Media accreditation required. WHERE: Lactalis Canada Rakely Plant, 25 Rakely Ct, Etobicoke, ON M9C 5G2 PHOTO OP: Following the ceremony and photo opportunity, media will have the chance to conduct 1:1 interviews with speakers. About Lactalis Canada Inc. With over 140 years of brand heritage, Lactalis Canada is the Canadian dairy leader behind iconic brands Cracker Barrel, Black Diamond, P'tit Québec, Balderson, Cheestrings Ficello, aMOOza!, Astro, Khaas, siggi's, IÖGO, IÖGO nanö, Olympic, Lactantia, Beatrice, Bfit, Enjoy!, Marie Morin Canada, Galbani, and Président. With more than 30 operating sites including 20 manufacturing facilities across Canada, the company and its more than 4000 employees are committed to enriching and nurturing the lives of Canadians through sustainable and responsible growth, high-quality products, contribution to communities and partnership with farmers, customers, partners and suppliers. Lactalis Canada has been named on Forbes' 2025 Best Employers in Canada and one of Greater Toronto's Top Employers for 2025. The company is part of Lactalis Group, the world's leading dairy company, headquartered in Laval, France. For more information, visit Media Contact: Lactalis Canada Media Relations [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
